Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2023 Readersâ Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Fate Therapeutics, Inc.
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
March 19, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics to Present at Upcoming March Investor Conferences
March 01, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 26, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
January 08, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 13, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
November 08, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
October 25, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics to Present at Upcoming September Investor Conferences
August 31, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
August 08, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
July 28, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics to Present at Upcoming June Investor Conferences
May 31, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
May 03, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
April 24, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics to Present at Upcoming March Investor Conferences
March 03, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 28, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
February 13, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
January 05, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
December 10, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
December 13, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
December 10, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
November 07, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics to Present at Upcoming Investor Conferences
November 04, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
November 03, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting
November 03, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
October 24, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting
October 05, 2022
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Tickers
FATE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.